

KABRADRUGSLIMITED

CIN-L02423MP1989PLC005438

To
Department of Corporate Services,
BSE Limited,
P J Tower, Dalal Street
Mumbai-400001

30 July 2023

Sir/ Madam,

Subject: Reconciliation of Share Capital Audit for Q.E. 30.06.2023- Submission of – Reg. Reference: Kabra Drugs Limited (524322).

With reference to above, we hereby enclose the Reconciliation of Share Capital Audit for quarter ended 30th June 2023 from Practicing Company Secretary.

This is for your information and record.

Thanking you,

Yours faithfully

For, KABRA DRUGS LIMITED

DIRECTOR / AUTHORISED SIGNATORY

GS CO POLOS EN TERMINE



30th July 2023 To,

BSE LIMITED

Dear Sir,

Sub: Reconciliation of Share Capital Audit Report for the quarter ended 30th June 2023

We are enclosing herewith the Reconciliation of Share Capital Audit report of M/s. KABRA DRUGS LIMITED for the quarter ended 30^{th} June 2023.

Thanking You,

Yours faithfully,

Narasimhan Srividhya Practicing Company Secretary

RECONCILIATION OF SHARE CAPITAL AUDIT REPORT

1 For Quarter Ended

30th June 2023

2 ISIN:

INE23K01017

3 Face Value:

Rs. 10/- per share

4 Name of the Company

KABRA DRUGS LIMITED

5 Registered Office Address

270 Shastri Market Indore MP 452007 IN

6 Correspondence Address

Same as above

Tel.No. 0731-2971305/6501305

7 Telephone & Fax Nos.

8 Email address

kabradrugs@rediffmail.com

9 Names of the Stock Exchanges where the company's securities are listed

Bombay Stock Exchange Ltd.

- 10 Issued Capital
- 11 Listed Capital (Exchange-wise) (as per company's records)
 Bombay Stock Exchange Ltd:
- 12 Held in dematerialized form in CDSL
- 13 Held in dematerialized form in NSDL
- 14 Physical
- 15 Total No. of shares (12+ 13+ 14)
- Reasons for difference if any, between (10&11), (10&15),

Number of shares	% of Total Issued Capital	
43,88,600	100%	
12,00,156	27.34	
17,30,043	39.43	
14,58,401	33.23	
43,88,600	100.00%	

Certifying the details of changes in share capital during the quarter under consideration as per Table below:

Particulars	No.of Shares	Applied /Not Applied for listing	Listed on Stock Exchanges (specify Names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Appr. Pending for SE (specify
-------------	-----------------	---	---	---------------------------	---------------------------	--



			Names)
		1	
 	 Nil	 	

***Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, Any other (to specify).

Register of Members is Updated (Yes/No)

If not, updated up to which date

YES	
Not Applicable	

Reference of Previous Quarter with 19 regards to excess dematerialized shares, if any

Nil	

Has the company resolved the matter mentioned in Point No. 19 above in the current quarter? If not, reason why?

Not Applicable	

Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:

Total No. of demat requests	No. of requests	No. of Shares	Reasons for delay
Confirmed after 21 Days	Nil	Nil	NA
Pending for more than 21 days	Nil	Nil	NA

Name, Telephone and Fax No. of the Compliance officer of the Co.

Mrs.MONIKA NISHANT GATTANII, Company Secretary Ph: 022-28523437

Name, Address, Tel .& Fax No., Regn. No of the Auditor

NarasimhanSrividhya Company Secretaries in Practice-CP.No.14058 No.52,Sundarabhavanam, 1st floor,4tha venue, ashok nagar,chennai - 6000333 e-mail id-srividhya0806@gmail.com Phone No.-9791712781



Appointment of common agency for share 24 registry work If yes (name & address)

M/s. Skyline Financial Services Pvt. Ltd. A/505, Dattani Plaza, Andheri Kurla Road, Safeed Pool, Mumbai- 400072.

Any other detail that the auditor may like to provide. (e.g.BIFR Company, delisting from SE, company changed its name etc.)

-----Nil-----

Date: 30th July 2023 Place: Chennai NS Jula

Narasimhan Srividhya Practicing Company Secretary CP No.14058

UDIN:A034428E000706176 Peer Review Certificate No:829/2020 Unique Code:P2004TN081200

> NARASIMHAN SRIVIDHYA Company Secretary In Practice Mem. No : 34428 Cop : 14058